Sabra Health Care REIT (SBRA) Insider Foster Buys 8,310 Shares

Insider Michael Foster bought 8,310 shares of Sabra Health Care REIT, Inc. (SBRA) on June 17, 2026. The shares were acquired at a total value of $150,000 based on the trading price of $18.12 on that date. This purchase comes as the stock hovers near its 52-week low of $17.17.

Inside Michael Foster's Trade

Foster's recent purchase adds to the group of insiders who have been buying shares, indicating confidence in the company’s future. Alongside him, other insiders like Craig Barbarosh, Jeffrey Malehorn, and Catherine Cusack also bought 8,310 shares each on the same day. This activity reflects a coordinated effort among insiders to reinforce their commitment to Sabra Health Care REIT.

Other Institutional Activity in Sabra Health Care REIT

Several notable institutional investors hold positions in Sabra Health Care REIT. BlackRock Inc. grew its position by 2,514,143 shares, ending with 41,614,351 shares valued at about $803.2 million. Vanguard Portfolio Management LLC added 208,297 shares to its holdings, bringing its total to 23,352,373 shares worth roughly $450.7 million. State Street Corporation also increased its stake by 205,699 shares, totaling 12,305,655 shares valued at approximately $237.5 million.

Sabra Health Care REIT, Inc. Stock Down 8.2%

Currently, Sabra Health Care REIT trades at $18.12, which is near its 52-week low and below its 200-day moving average of approximately $19.93. The stock has seen some fluctuations recently but has remained stable as it approaches its next earnings date on November 4, 2026.

Recent Earnings

In its latest earnings report, Sabra Health Care REIT reported revenue of $863.8 million, marking a growth rate of 25.3% compared to the previous year. The company has a net margin of 7.6% and a return on equity (ROE) of 2.4%. Investors will be looking forward to the upcoming earnings call scheduled for November 4, 2026.

Dividend

Sabra Health Care REIT pays an annual dividend of $1.20, resulting in a yield of 6.04%. This makes the stock appealing to income-focused investors, especially as it maintains a payout ratio of 4.6%, indicating sustainable returns to shareholders.

Analysts Set New Price Targets

Analysts have been busy adjusting their views on Sabra Health Care REIT. On October 13, 2026, UBS maintained its Neutral rating with a price target of $20.00, down from $21.00. Barclays also maintained its Equal-Weight rating, lowering its target from $23.00 to $21.00 on the same day. Currently, the consensus price target among 14 analysts is $22.79, suggesting potential upside for the stock from its current level.

About Sabra Health Care REIT

Sabra Health Care REIT, Inc. is a real estate investment trust focused on owning and investing in healthcare-related real estate across the U.S. and Canada. The company operates from its headquarters in Tustin, California, and serves a vital role in the healthcare sector by providing properties that cater to healthcare needs. This recent insider buying activity highlights confidence in the company's future prospects.

Bottom Line

Investors should watch for Sabra Health Care REIT's upcoming earnings report on November 4, 2026, for insights into its financial health. The recent insider purchases may signal positive expectations among insiders, though the backward-looking nature of the earnings and trading reports should be kept in mind.